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baseline estimation of the brain protection by the retro- 
grade brain perfusion itself. 
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Reply to the Editor: 
We thank Watanabe and associates for their interest in 
our recent article, "Pharmacologic ntervention for isch- 
emic brain edema after retrograde cerebral perfusion. ''1 
We reported that the supply of oxygen or glucose by 
retrograde cerebral perfusion (RCP) was not enough to 
maintain sufficient cerebral metabolism and that this may 
cause brain edema after antegrade cerebral blood perfu- 
sion is resumed. We therefore recommended cerebral 
protection with pharmacologic agents to prevent neuro- 
logic complications during aortic arch operation with the 
use of RCP. 1 
Although RCP is widely used with satisfactory esults to 
protect he brain during aortic arch operation, the stan- 
dards for this procedure, such as perfusion site, drainage 
site, perfusion pressure, flow rate, and temperature, have 
not yet been established. 2 We agree with Watanabe and 
associates that drainage from the right atrium should 
increase the veno-venous shunt, which may reduce the 
cerebral protective ffect of RCP. As we explained in our 
article, however, the pressure gradient between the max- 
illary veins and systemic arteries caused retrograde cere- 
bral blood flow, which was evidenced by desaturated 
blood being returned to the carotid artery. Several clini- 
cal 3, 4 and experimental s studies have suggested the exis- 
tence of a veno-venous shunt that does not participate in 
cerebral metabolism during RCP, and the veno-venous 
shunt is considered a major disadvantage of RCP com- 
pared with antegrade selective cerebral perfusion. 
In our experimental studies, we observed that the 
cerebral blood flow provided uring RCP was only half of 
that supplied during cardiopulmonary b pass with hypo- 
thermia. 1 This finding was in accord with the results of 
other experimental studies. 2' 6 A limitation of our study 
was the determination of cerebral blood flow, including 
veno-venous hunt flow, as Watanabe and associates 
pointed out. It is difficult, however, to distinguish the true 
functional blood fl0w that participates in cerebral metab- 
olism from veno-venous shunt flow during RCP in the 
experimental study. Accurate measurement of the true 
functional blood flow, if possible, should enable us to 
precisely evaluate cerebral metabolism during RCP. We 
therefore hope that Watanabe and associates' experimen- 
tal study will clarify the true functional blood flow during 
RCP by means of laser photometry. 
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Individualized patient heparinization and 
protamine reversal 
To the Editor." 
We read with interest he article titled "The Impact of 
Heparin Concentration and Activated Clotting Time 
Monitoring on Blood Conservation" by Despotis and 
associates 1 in the July 1995 issue of the JOURNAL. This 
article examined an alternative anticoagulation manage- 
ment system (Hepcon HMS; Medtronic Hemotec, Engle- 
wood, Colo.) and blood conservation in adult cardiac 
surgical patients, highlighting once more the need for 
surgeons and anesthetists o reexamine their anticoagula- 
tion practices, which have remained largely unchanged for 
some two decades. 
The suggestion that it may be possible (and seemingly 
appropriate) to administer doses of heparin according to 
an individual patient's preoperative blood response to 
heparin (and to subsequently maintain this level on by- 
pass) may go someway toward eliminating "best fit" 
empirical protocols of heparin administration from the 
surgical arena. The fact that this dosage tailoring may be 
achieved without he need for increased administration of
protamine, with its recognised "heparin-protamine com- 
plex" morbid sequelae, provides greater impetus for this 
alternative regimen to be formally examined. This study 
also confirms previous work 2 from our unit with the 
Hepcon device, which suggested that empirical protamine 
administration protocols often result in excessive admin- 
istration. 
There is clearly a need to remain vigilant when one is 
confronted with the postoperative patient who is actively 
bleeding after increased heparin administration because 
heparin rebound may be a concern. Furthermore, a more 
thorough investigation of the determinants and markers 
of consumptive coagulopathy needs to be performed. We 
would be interested to learn whether the authors believe 
it is possible in the presence of heparin to draw firm 
conclusions regarding coagulation factor consumption 
solely on the basis of routine activated partial thrombo- 
plastin time and prothrombin time times. Perhaps less 
equivocal markers, such as fibrinopeptide A, thrombin- 
antithrombin complexes, or prothrombin fragment 1.2, 
may assist in confirming this event. 
Attempts to delineate purely heparin concentration- 
dependent postoperative s quelae from those of heparin- 
protamine complexes are currently under consideration 
within our unit, as are additional studies assessing the 
contribution of heparin-bonded cardiopulmonary b pass 
circuitry to the anticoagulation-neutralization equation. 
The contribution of Despotis and associates I is therefore 
timely and welcomed by our group. 
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Reply to the Editor: 
We support Martin and colleagues' recommendation that 
clinicians reexamine the anticoagulation protocols at their 
institutions. This contention is supported not only by our 
study I but also by the recent study of Jobes and coworkers. 2 
In response to the question regarding the role of heparin as 
a cause of bleeding, we agree that residual heparin may be a 
potential cause of excessive bleeding after cardiopulmonary 
bypass and should be evaluated with a sensitive assay (we 
used the heparinase activated clotting time). We do not 
believe that heparin was the cause of bleeding in the control 
group (C) however, because these patients actually received 
much less heparin than did patients in our intervention 
group (I). In patients with demonstrated xcessive intraop- 
erative bleeding (n = 101), our laboratory-based thrombin 
time assay, which is exquisitely sensitive to heparin (mea- 
surements prolonged to > 120 seconds with heparin concen- 
trations of 0.1 U/ml), did not demonstrate significant 
amounts of residual heparin in either group after arrival at 
the intensive care unit (C 24 -+ 15, I 27 +- 23 seconds, p = 
0.40). The greater prolongations in whole blood prothrom- 
bin time and activated partial thromboplastin time assays 
therefore almost certainly reflected greater eductions in 
coagulation factors in the control group. 
We recently explored this issue further in a subgroup of 
patients at high risk for excessive blood loss after extra- 
corporeal circulation (n = 31). 3 This study demonstrated 
that consumable coagulation factors V, VIII, and fibrin- 
ogen were preserved in patients in the intervention group 
in the setting of normal thrombin time results (C 22 _+ 5, 
i 20 _+ 4 seconds, p = 0.11). In addition, maintenance of
higher heparin concentrations in our intervention group 
resulted in reduced activation of coagulation and fibrin- 
olysis, as demonstrated by lower fibrinopeptide A levels 
(p = 0.0002), lower D-dimer (p = 0.03) levels, and a trend 
toward lower prothrombin fragment 1.2 (p = 0.06) levels 
in Specimens obtained before discontinuation of cardio- 
pulmonary bypass9 This confirms previous published ata 
indicating that fibrinopeptide A levels are indirectly re- 
lated to heparin concentration. 4' s Although the potential 
role of optimized protamine doses on reduced blood 
product use was not fully addressed, our data provide 
